Primary Healthcare’s Net operating cash flow was down 39.3% to $90.4m. Outlook: “As a result of HY 2017 trading, the subdued environment reflected in the Medicare data, and ongoing uncertainty over Government policy and regulations, Primary now expects underlying NPAT for FY 2017 to be in the range of $92 million to $102 million, subject to trading conditions in the remainder of the year and the outcome of any Government policy reviews. This compares with $96.8 million underlying NPAT from continuing operations in FY 2016.” First impressions for Boral, Sonic Healthcare and Inghams Group below:


Boral: Net operating cash flow up 39.7% to $158m Divisional EBIT: Boral Australia (66% of rev) EBIT down 3% to $164m; USG Boral (15% of rev) up 28% to $117m; Boral USA (19% of rev) $13m. | Outlook: Boral’s outlook for FY2017 remains largely unchanged, with Boral’s EBIT expected to be higher than the EBIT delivered in FY2016, with improved performance partially offset by the loss of EBIT of ~$6.5 million associated with the divestment of Boral’s 40% share of Boral CSR Bricks in Nov-16.  (VIEW LINK)

Sonic Healthcare: Net operating cash flow up 2.6% to $333.2m | Constant currency revenue growth was 5%, driven mainly by growth in Germany 6% and Switzerland 8%; the UK- 3% and Belgium (flat) experienced a slowdown. Australian Pathology grew 7% (4% was organic). Organic cc growth in US Pathology was 3.3%. Imaging organic growth was 4%. | Outlook: Sonic guided to FY17 CC EBITDA growth of 5% +.  (VIEW LINK)

Inghams Group: EBIT up 8.6% to $76.9m and EBIT margin 6.3% | Net operating cash flow up 11% to $79.2m | Outlook: “The company reconfirms that its FY17 prospectus forecast of $98.8M pro forma NPAT is expected to be achieved based on the current trading outlook. Reconfirm intention to pay fully franked dividends of 65 – 70% of pro forma NPAT.”:    (VIEW LINK)


Please sign in to comment on this wire.